Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 15/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.87 |
| ▸ | RARG | P13631 | 1/20 | 0.87 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL29530259 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL7052472 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL5169 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL11957687 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3375739 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL6976956 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL1489117 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3377103 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL5468691 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3381790 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194474-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-07-10 | — | — | US | claimed |
| US-20130040996-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-02-14 | — | — | US | claimed |
| US-20260091038-A1 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | MASSACHUSETTS INST TECHNOLOGY (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | UNIV GEORGIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260035448-A1 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | SCHOLAR ROCK INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12486318-B2 | Anti-guanosine antibody as a molecular delivery vehicle | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4638496-A1 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | Scholar Rock, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12440497-B2 | Compositions and methods for enhancing Wnt signaling for treating cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250262209-A1 | TREATMENT OF GASTROINTESTINAL DISEASES | ACLIPSE TWO INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250235415-A1 | MODULATION OF HUMAN BREAST MILK COMPOSITION | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2025-07-24 | — | — | US | disclosed |
| US-12338279-B2 | Selective and potent inhibitory antibodies of myostatin activation | SCHOLAR ROCK, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| EP-2213289-A1 | Combination treatment for diabetes mellitus | Nycomed GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| WO-2010015818-A1 | RESPIRATORY DISEASE TREATMENT | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| EP-1874308-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | Nycomed GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006094933-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040996-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | CDK4, PPARD, CCND1 | PPARG 10/4885RXRA 1836/4885RARG 2202/4885 |
| US-20260091038-A1 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | WNT3A, APC, WNT3 | PPARG 4269/4885RXRA 3453/4885RARG 3954/4885 |
| US-12486318-B2 | Anti-guanosine antibody as a molecular delivery vehicle | SSB, CHMP4B, LAMP2 | PPARG 3861/4885RXRA 3772/4885RARG 2499/4885 |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | PPARG 1/4885RXRA 12/4885RARG 15/4885 |
| US-20140194474-A1 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF | CDK4, PPARD, CCND1 | PPARG 10/4885RXRA 1836/4885RARG 2202/4885 |
| US-20250262209-A1 | TREATMENT OF GASTROINTESTINAL DISEASES | FABP6, SLC10A2, FABP2 | PPARG 17/4885RXRA 275/4885RARG 448/4885 |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | APOL1, APOB, LY96 | PPARG 3516/4885RXRA 1188/4885RARG 3029/4885 |
| US-12440497-B2 | Compositions and methods for enhancing Wnt signaling for treating cancer | APC, WNT3A, WNT3 | PPARG 4227/4885RXRA 3570/4885RARG 3080/4885 |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | IL5, PPARD, PPARG | PPARG 3/4885RXRA 191/4885RARG 90/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | PPARG 149/4885RXRA 777/4885RARG 1658/4885 |
| US-20260035448-A1 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | IGF2BP2, MYO1G, IGF2BP1 | PPARG 4240/4885RXRA 2968/4885RARG 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.